TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28853979
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day for 6 months
Study: 21091877
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg/day for up to 34 weeks
Study: 16267603
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg in the morning, placebo at bedtime
Study: 16267603
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg at bedtime, placebo in the morning
Study: 16267603
Drug: Placebo (glucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose) in the morning, amitriptyline 25 mg at bedtime
Study: 3304951
Drug: Cyclandelate at
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate at a dosage of 1600 mg/day
Study: 24035327
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation (CCRT) with fluorouracil (5‐FU) plus mitomycin
Study: 21346001
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist pergolide given orally
Study: 11220553
Drug: Sibutramine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, maintained at 20 mg through week 24)
Study: 9123738
Drug: Neoadjuvant combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant combination therapy with flutamide and LHRH agonist for 3 months before radical prostatectomy
Study: 8473453
Drug: Levonorgestrel (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (0.75 mg for two doses 12 h apart)
Study: 27245783
Drug: Intratympanic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic lidocaine and dexamethasone (ITLD) injection
Study: 27245783
Drug: Intratympanic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic saline injection (Control)
Study: 24723218
Drug: Group art
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group art therapy
Study: 22745140
Drug: Curcuminoid (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid (30 mg 3 times daily)
Study: 22745140
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (25 mg 3 times daily)
Study: 31099215
Drug: Electroacupuncture nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture nerve stimulation therapy (ENST), 50 min per session, three times a week for 3 months
Study: 31099215
Drug: Perfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion therapy of four‐medication combination (heparin sodium, lidocaine, sodium bicarbonate, gentamicin sulfate), twice a week for the first 6‐8 weeks, then twice per month for 3 months
Study: 28530451
Drug: High-Volume Injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Volume Injection (HVI)
Study: 22348468
Drug: DHA-enriched fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched fish oil supplement (250 mg DHA/d and 60 mg EPA/d)
Study: 17629042
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) at 0, 2, and 6 weeks, then every 8 weeks
Study: 17629042
Drug: Methylprednisolone (0.8-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (0.8-1 mg/kg daily for 3 weeks, then tapering)
Study: 11904593
Drug: Self-sampling methods
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-sampling methods (2 sequential swabs)
Study: 10935831
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione (GSH) 600 mg intramuscularly for 12 weeks
Study: 10935831
Drug: Symptomatic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapies for 12 weeks
Study: 2021388
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular triamcinolone (360 mg over the first three days)
Study: 2021388
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisone (median dose 12.5 mg per day)
Study: 2021388
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular triamcinolone
Study: 6302831
Drug: pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 200 mg t.i.d. for 1 week
Study: 31806543
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg) subcutaneously every 3-4 weeks for about 6 months, then every 12 weeks for a total duration of 5 years.
Study: 26634615
Drug: ICG-guided antihypertensive
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-guided antihypertensive therapy
Study: 26634615
Drug: Empiric antihypertensive
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antihypertensive therapy
Study: 22005661
Drug: Subepineural injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subepineural injection at the neural bifurcation
Study: 22005661
Drug: Separate postbifurcation
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate postbifurcation injections around the tibial and peroneal nerves
Study: 19126874
Drug: Resistant maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant maltodextrin (RMD) 6 g in drinks
Study: 19126874
Drug: Resistant maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant maltodextrin (RMD) 6 g in solid foods
Study: 7625347
Drug: Standard-phosphorus (215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-phosphorus (215 micrograms/kJ, or 90 mg/100 kcal)
Study: 7625347
Drug: Moderate-phosphorus (254
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-phosphorus (254 micrograms/kJ, or 106 mg/100 kcal)
Study: 7625347
Drug: High-phosphorus (287
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phosphorus (287 micrograms/kJ, or 120 mg/100 kcal)
Study: 28912116
Drug: Tablet-based EORTC
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based EORTC QLQ-C30 questionnaire
Study: 22000938
Drug: Overall (across
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (across medication phases)
Study: 2229897
Drug: Punctum plug
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punctum plug treatment on one side
Study: 28285255
Drug: 8h time
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8h time in bed (TIB) restriction with fluoxetine 20-40 mg
Study: 28285255
Drug: 6h time
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6h time in bed (TIB) restriction with fluoxetine 20-40 mg
Study: 25417042
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) using a pressure threshold device, 5 sessions weekly for 12 weeks, 30 mins/day
Study: 16942534
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) vs Tadalafil (20 mg)
Study: 16942534
Drug: Vardenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (20 mg) vs Tadalafil (20 mg)
Study: 16942534
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg) vs Sildenafil (100 mg)
Study: 9327830
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs (aspirin, ticlopidine, thromboxane A2 receptor inhibitors)
Study: 9327830
Drug: Antithrombotics (heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotics (heparin, hirudin, hirulog)
Study: 9327830
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, HMG‐CoA reductase inhibitors, fish‐oil supplements
Study: 9327830
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers, nitric oxide donors
Study: 18548088
Drug: Relaxation therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapies
Study: 10099724
Drug: Portable liquid
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portable liquid oxygen therapy (PLOT)
Study: 1879247
Drug: Colloidal aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal aqueous solution of vitamin E (acetate ester)
Study: 1879247
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil solution of vitamin E
Study: 7092487
Drug: Repeated MAO-inhibitor
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated MAO-inhibitor treatment (crossover study of clorgyline and pargyline)
Study: 24957712
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy treatment for neck pain
Study: 9847269
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm of the preventive therapy study
Study: 8018457
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (1 ng min‐1 kg‐1)
Study: 3698464
Drug: Indomethacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (200 mg)
Study: 8018457
Drug: Indomethacin pre‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin pre‐treatment followed by angiotensin II infusion
Study: 8018457
Drug: Frusemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (20 mg) administration
Study: 2529659
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting applied for 8 weeks (at least 12 hours a day)
Study: 10490109
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting
Study: 26490109
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (comparator group)
Study: 18603026
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg/day
Study: 18603026
Drug: Acetazolamide 500
Normalized name: acetazolamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 500 mg/day
Study: 8196151
Drug: Pravastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (5 mg or 10 mg twice a day)
Study: 30535670
Drug: PR-fampridine 10
Normalized name: amifampridine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-fampridine 10 mg twice daily
Study: 28973344
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm decreased to 10 ppm between 72 and 96 hours, then to 5 ppm until completion of therapy for 24 days)
Study: 21556911
Drug: Protocol D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol D (saline chaser at 8 mL/s)
Study: 21556911
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (saline chaser at 4 mL/s)
Study: 18482014
Drug: RCAC (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCAC (1% formulation applied twice a day for 28 days)
Study: 18482014
Drug: Placebo (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (applied twice a day for 28 days)
Study: 18482014
Drug: RCAC (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCAC (in vitro treatment)
Study: 17130317
Drug: Sequential pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pneumatic leg pump therapy postoperatively
Study: 17130317
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pneumatic leg pump therapy)
Study: 8928893
Drug: Double pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double pharmacological autonomic blockade with propranolol (0.2 mg/kg iv) and atropine (0.04 mg/kg iv)
Study: 1471411
Drug: B subunit‐whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit‐whole cell vaccine (B‐WC)
Study: 6375258
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 and 2.0 mg)
Study: 27658218
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) plus medication (zolpidem)
Study: 27658218
Drug: CBT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT and intermittent medication (prn)
Study: 27658218
Drug: CBT without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT without additional treatment
Study: 22475857
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses PENTA, then Dose 4 DTaP and Hib
Study: 22475857
Drug: 4 QUAD
Normalized name: influenza virus vaccine 2023-2024 Quadrivalent Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 QUAD doses and Hib
Study: 22475857
Drug: 4 PENTA
Normalized name: Pentam
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 PENTA doses
Study: 22475857
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib)
Study: 17084512
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: vinblastine (0.2 mg/kg on day 1), etoposide (100 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and bleomycin (30 mg on days 1, 8, and 15)
Study: 17084512
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: etoposide (350 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and cyclophosphamide (1600 mg/m2/d on days 2-5)
Study: 10073421
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (61 to 240 mo)
Study: 10073421
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (0.7 to 6 mo)
Study: 7675967
Drug: (+)-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-fenfluramine (30 mg po)
Study: 2105409
Drug: Formaldehyde vapor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formaldehyde vapor exposure at levels of 0.85 mg/m3, 0.12 mg/m3, and 0.008 mg/m3 for 90 min
Study: 6255005
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (1.2-2.5 mg/day)
Study: 31836196
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg, increased to 300 mg as tolerated)
Study: 30231896
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks for 68 weeks
Study: 30231896
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks for 68 weeks
Study: 27431341
Drug: Psychoeducation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation with problem-solving (PEPS) therapy plus usual treatment
Study: 24162943
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment alone
Study: 27431341
Drug: Psychoeducation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation with problem-solving (PEPS) therapy
Study: 25514875
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (Group D: 0 Joules)
Study: 17453860
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17beta‐estradiol + 0.1 mg NETA
Study: 17453860
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17beta‐estradiol + 0.25 mg NETA
Study: 15168036
Drug: Olive oils
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oils with increasing phenolic concentration (0 to 150 mg/Kg)
Study: 12114917
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (3 doses, 800 microg each)
Study: 10049275
Drug: Abacavir 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir 4 mg/kg
Study: 10049275
Drug: Abacavir 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir 8 mg/kg
Study: 10049275
Drug: Abacavir (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir (both doses)
Study: 526385
Drug: Ketamine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine i.v. infusion
Study: 24519448
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus laser therapy (ice chips for 1 h 35 min followed by low-level laser therapy, InGaAIP, 660 nm, 40 mW, 6 J/cm(2), n = 54)
Study: 24519448
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy alone (n = 17)
Study: 24519448
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific treatment for OM, n = 33)
Study: 23440253
Drug: Weekly volunteering
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly volunteering with elementary school‐aged children for 2 months
Study: 10525745
Drug: Triple the
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple the maintenance dose every 72 h
Study: 10525745
Drug: Double the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double the maintenance dose every 48 h
Study: 10525745
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose every 24 h
Study: 8546911
Drug: ICR62 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICR62 2.5 mg
Study: 8546911
Drug: ICR62 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICR62 10 mg
Study: 8546911
Drug: ICR62 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICR62 20 mg
Study: 8546911
Drug: ICR62 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICR62 40 mg
Study: 8546911
Drug: ICR62 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICR62 100 mg
Study: 1884746
Drug: HR (2
Normalized name: Yttrium Y-90 n-((4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl)-d-phe-cys-tyr-d-trp-lys-thr-cys-thr (2-7)disulfide
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR (2 tablets of 500 mg/day)
Study: 6346476
Drug: Estradurin/Etivex (estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradurin/Etivex (estrogen preparation)
Study: 27327283
Drug: Ranibizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 1.0 mg
Study: 27327283
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg and 1.0 mg
Study: 22027845
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 150 mg/day
Study: 22045039
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (150 and 300 mg/day)
Study: 22045039
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 150 mg/day and Escitalopram
Study: 21146654
Drug: Standard activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard activated clotting time (ACT)-guided doses of intravenous UFH
Study: 21146654
Drug: Non-ACT-guided weight-adjusted
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACT-guided weight-adjusted low dose of intravenous UFH
Study: 21146654
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (Standard and Low-dose)
Study: 16282047
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments for OA
Study: 9499327
Drug: Thalidomide 300
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 300 mg/d
Study: 9499327
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg/d and 300 mg/d
Study: 29190605
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of colistin
Study: 29190605
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of colistin
Study: 25622198
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking cessation (CSC) intervention
Study: 25622198
Drug: Daily assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessments during CSC
Study: 31365529
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Study: 31365529
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 4% articaine with 1:100,000 epinephrine